Printer Friendly

NEW ADVERTISING AND PUBLIC RELATIONS CAMPAIGNS FOR WOBENZYM N, EUROPE'S LARGEST-SELLING ENZYME SYSTEM, DISCLOSED BY MUCOS PHARMA

 SCOTTSDALE, Ariz., Feb. 4 /PRNewswire/ -- Mucos Pharma GmbH, the Munich, Germany-based multinational biochemical manufacturer, is changing the focus of its national advertising and public relations campaigns in the United States for Wobenzym N, Europe's top-selling enzyme system, to stress its ability to utilize the human body's vitamin content more effectively. The additional aim of the change is to better the understanding of the American public of the efficacy of the system.
 In developing Wobenzym N over a period of 30 years at a cost exceeding $50 million, Dr. Karl Ransberger, founder and president of Mucos, Europe's largest privately owned company of its kind, had two purposes in mind. The first was to render the body more capable of utilizing its various enzymes. The second was to aid the body's absorption of vitamins.
 That both these goals have been reached has been demonstrated by the fact that 1 billion tablets are sold throughout the world, 500 million in Europe and an additional 500 million elsewhere.
 -0- 2/4/93
 /CONTACT: John Strauss of John Strauss/Communifax, 310-552-9800, for Mucos Pharma GmbH/


CO: Mucos Pharma GmbH ST: Arizona IN: MTC SU:

BP-LS -- LA007 -- 2805 02/04/93 09:15 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:198
Previous Article:MANUFACTURERS OFFERS NEW ENVIRONMENTAL TECHNOLOGY BREAKTHROUGH FOR MASS-PRODUCED HOUSING
Next Article:H.F. AHMANSON ANNOUNCES OFFERING OF PREFERRED STOCK
Topics:


Related Articles
DRUG INDUSTRY EXCITED BY INTRODUCTION INTO UNITED STATES OF WOBENZYM N, EUROPE'S LARGEST SELLING ENZYME FORMULA
DRUG INDUSTRY EXCITED BY INTRODUCTION INTO UNITED STATES OF WOBENZYM N, EUROPE'S LARGEST SELLING ENZYME FORMULA
New Hope for a Rare Form of Cancer; Makers of Wobenzym Seek Orphan Drug Status for Wobe-Mugos.
FDA Reviews Orphan Drug Application to Treat Multiple Myeloma With Oral Enzyme Formula.
Can a Pineapple Prevent a Heart Attack?
Olympic Team Finds Systemic Enzymes Effective for Sports Injuries.
Naturally Vitamins Extends Contract for Exclusive Distribution Rights Of Wobenzym(R)N in the United States; Best-Selling Systemic Enzyme Formula...
American court confirms Atrium's exclusive U.S. rights to the renowned Wobenzym(R) N.
American court confirms Atrium's exclusive US rights to the renowned Wobenzym[R]N.
Douglas Laboratories presents new Wobenzym professional strength.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters